# Apollo Commercial Real Estate Finance, Inc.: financial statements, quarterly

ARI · NYSE · CIK 1467760 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ari.md) · [Financials](/companies/ari/financials.md) · [Filings](/companies/ari/filings.md) · [Insiders](/companies/ari/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ari/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [81.2](/filings/0000950170-24-119007.md) | [84.2 d](/filings/0001193125-26-044725.md) | [80.5](/filings/0000950170-25-058066.md) | [81.1](/filings/0000950170-25-099645.md) | [71.6](/filings/0001193125-25-258572.md) | [70.5 d](/filings/0001193125-26-044725.md) | [65.8](/filings/0001193125-26-187094.md) | [70.9](/filings/0001193125-26-342628.md) | [61.6](/filings/0001193125-25-258572.md) | [73.3 d](/filings/0001193125-26-044725.md) | [58.6](/filings/0001193125-26-187094.md) | [44.4](/filings/0001193125-26-342628.md) |
| Interest expense | $m | [122](/filings/0001467760-23-000019.md) | [123 d](/filings/0001467760-24-000010.md) | [128](/filings/0001467760-24-000033.md) | [128](/filings/0000950170-24-091841.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0000950170-24-119007.md) | [(0.1) d](/filings/0001193125-26-044725.md) | [0.1](/filings/0000950170-25-058066.md) | [0.1](/filings/0000950170-25-099645.md) | [0.1](/filings/0001193125-25-258572.md) | [0.1 d](/filings/0001193125-26-044725.md) | [0.1](/filings/0001193125-26-187094.md) | [0.1](/filings/0001193125-26-342628.md) | [0.2](/filings/0001193125-25-258572.md) | [(0.1) d](/filings/0001193125-26-044725.md) | [0.2](/filings/0001193125-26-187094.md) | [0.0](/filings/0001193125-26-342628.md) |
| Net income | $m | [46.1](/filings/0000950170-24-119007.md) | [46.5 d](/filings/0001193125-26-044725.md) | [(105)](/filings/0001193125-25-258572.md) | [35.8](/filings/0001193125-25-258572.md) | [(91.5)](/filings/0001193125-25-258572.md) | [40.7 d](/filings/0001193125-26-044725.md) | [26.0](/filings/0001193125-26-342628.md) | [20.7](/filings/0001193125-26-342628.md) | [50.8](/filings/0001193125-25-258572.md) | [29.2 d](/filings/0001193125-26-044725.md) | [26.2](/filings/0001193125-26-342628.md) | [25.8](/filings/0001193125-26-342628.md) |
| Diluted EPS | $ per share | [0.30](/filings/0000950170-24-119007.md) | not reported | [(0.76)](/filings/0000950170-25-058066.md) | [0.23](/filings/0000950170-25-099645.md) | [(0.69)](/filings/0001193125-25-258572.md) | not reported | [0.16](/filings/0001193125-26-187094.md) | [0.12](/filings/0001193125-26-342628.md) | [0.34](/filings/0001193125-25-258572.md) | not reported | [0.16](/filings/0001193125-26-187094.md) | [0.11](/filings/0001193125-26-342628.md) |
| Basic EPS | $ per share | [0.30](/filings/0000950170-24-119007.md) | not reported | [(0.76)](/filings/0000950170-25-058066.md) | [0.23](/filings/0000950170-25-099645.md) | [(0.69)](/filings/0001193125-25-258572.md) | not reported | [0.16](/filings/0001193125-26-187094.md) | [0.12](/filings/0001193125-26-342628.md) | [0.34](/filings/0001193125-25-258572.md) | not reported | [0.16](/filings/0001193125-26-187094.md) | [0.11](/filings/0001193125-26-342628.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0001467760-23-000019.md) | [0.2](/filings/0000950170-25-017122.md) | [0.2](/filings/0001467760-24-000033.md) | [0.2](/filings/0000950170-24-091841.md) | [0.2](/filings/0000950170-24-119007.md) | [0.3](/filings/0001193125-26-044725.md) | [0.2](/filings/0000950170-25-058066.md) | [0.2](/filings/0000950170-25-099645.md) | [0.2](/filings/0001193125-25-258572.md) | [0.1](/filings/0001193125-26-342628.md) | [0.1](/filings/0001193125-26-187094.md) | [1.2](/filings/0001193125-26-342628.md) |
| Total assets | $bn | [9.2](/filings/0001467760-23-000019.md) | [9.3](/filings/0000950170-25-017122.md) | [9.2](/filings/0001467760-24-000033.md) | [9.3](/filings/0000950170-24-091841.md) | [9.1](/filings/0000950170-24-119007.md) | [8.4](/filings/0001193125-26-044725.md) | [8.8](/filings/0000950170-25-058066.md) | [9.8](/filings/0000950170-25-099645.md) | [9.5](/filings/0001193125-25-258572.md) | [9.9](/filings/0001193125-26-342628.md) | [10.1](/filings/0001193125-26-187094.md) | [2.1](/filings/0001193125-26-342628.md) |
| Total liabilities | $bn | [6.9](/filings/0001467760-23-000019.md) | [7.1](/filings/0000950170-25-017122.md) | [7.2](/filings/0001467760-24-000033.md) | [7.3](/filings/0000950170-24-091841.md) | [7.2](/filings/0000950170-24-119007.md) | [6.5](/filings/0001193125-26-044725.md) | [6.9](/filings/0000950170-25-058066.md) | [8.0](/filings/0000950170-25-099645.md) | [7.7](/filings/0001193125-25-258572.md) | [8.0](/filings/0001193125-26-342628.md) | [8.3](/filings/0001193125-26-187094.md) | [0.9](/filings/0001193125-26-342628.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [2.2](/filings/0000950170-24-119007.md) | [2.2](/filings/0001193125-26-044725.md) | [2.0](/filings/0001193125-25-258572.md) | [2.0](/filings/0001193125-25-258572.md) | [1.9](/filings/0001193125-25-258572.md) | [1.9](/filings/0001193125-26-342628.md) | [1.9](/filings/0001193125-26-342628.md) | [1.8](/filings/0001193125-26-342628.md) | [1.9](/filings/0001193125-25-258572.md) | [1.9](/filings/0001193125-26-342628.md) | [1.8](/filings/0001193125-26-342628.md) | [1.3](/filings/0001193125-26-342628.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [83.4 d](/filings/0000950170-24-119007.md) | [30.8 d](/filings/0001193125-26-044725.md) | [52.8](/filings/0000950170-25-058066.md) | [50.2 d](/filings/0000950170-25-099645.md) | [47.2 d](/filings/0001193125-25-258572.md) | [49.9 d](/filings/0001193125-26-044725.md) | [39.3](/filings/0001193125-26-187094.md) | [63.2 d](/filings/0001193125-26-342628.md) | [31.7 d](/filings/0001193125-25-258572.md) | [8.2 d](/filings/0001193125-26-044725.md) | [12.6](/filings/0001193125-26-187094.md) | [33.9 d](/filings/0001193125-26-342628.md) |
| Dividends paid | $m | [50.5 d](/filings/0000950170-24-119007.md) | [50.5 d](/filings/0001193125-26-044725.md) | [50.8](/filings/0000950170-25-058066.md) | [50.6 d](/filings/0000950170-25-099645.md) | [49.3 d](/filings/0001193125-25-258572.md) | [35.2 d](/filings/0001193125-26-044725.md) | [35.4](/filings/0001193125-26-187094.md) | [35.3 d](/filings/0001193125-26-342628.md) | [34.7 d](/filings/0001193125-25-258572.md) | [35.8 d](/filings/0001193125-26-044725.md) | [35.6](/filings/0001193125-26-187094.md) | [34.8 d](/filings/0001193125-26-342628.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-119007.md) | [0.0 d](/filings/0001193125-26-044725.md) | not reported | not reported | [2.9 d](/filings/0001193125-25-258572.md) | [0.0 d](/filings/0001193125-26-044725.md) | [0.0](/filings/0001193125-26-187094.md) | [0.0 d](/filings/0001193125-26-342628.md) | [0.0 d](/filings/0001193125-25-258572.md) | [0.0 d](/filings/0001193125-26-044725.md) | [30.3](/filings/0001193125-26-187094.md) | [93.2 d](/filings/0001193125-26-342628.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [164](/filings/0001467760-23-000019.md) | [155](/filings/0001467760-24-000033.md) | [141](/filings/0000950170-24-091841.md) | [141](/filings/0000950170-24-119007.md) | [142](/filings/0000950170-25-058066.md) | [141](/filings/0000950170-25-099645.md) | [138](/filings/0001193125-25-258572.md) | [139](/filings/0001193125-26-187094.md) | [139](/filings/0001193125-26-342628.md) | [140](/filings/0001193125-25-258572.md) | [140](/filings/0001193125-26-187094.md) | [132](/filings/0001193125-26-342628.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 128,212,093 at 2026-08-07, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342628.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.